

DAKTARI BIOTECHNOLOGY LTD.

MEDICINE AND VACCINE INVESTMENT SHARES

INTRODUCTION & INVESTMENT TERMS

1. Introduction

- 1.1. This shares investment is established for investing in shares of Daktari Biotechnology limited company.
- 1.2. The company is founded for the purpose of research and production of medicine and vaccines in Kenya.
- 1.3. This agreement shall be executed by the person signing and Daktari Biotechnology limited.

2. Investment and Investor Terms

- 2.1. An investor is a person signing this shares investment.
- 2.2. The investor in signing shall invest a minimum of Kshs 200,000 and can invest as many multiples of Kshs 200,000.
- 2.3. Each investment shall be allocated shares at the value set following investment.

MEDICINE AND VACCINE EDUCATION, RESEARCH AND PRODUCTION

3. Diaspora University Trust Statement

- 3.1. The vaccine and medicine research and production facilities will be built at Diaspora University Town, a development by Diaspora University Trust.
- 3.2. The vaccine and medicine research and production will be done through Daktari Biotechnology limited a company founded by Diaspora University Trust, Scientists founders and Investors.
- 3.3. Daktari Biotechnology limited will work hand in hand with the university departments of biology and biotechnology; chemistry and biochemistry; and other university departments to advance education and research.

4. Founding Scientists and Scientists Statements

- 4.1. The founding scientists are: Dr. Wilson Endege, Dr. Benson Edagwa, Dr. Bernard Ayanga, Dr. Patrick Shompole, Dr; Steven Kemp, Prof. Frederick Boyce and other scientists who may join them.
- 4.2. Individual founding scientists are inventors or co-inventors of technology that will be put in as capital for application of the production of medicine and vaccines.
- 4.3. The founding scientists state that they have experience in the fields of medicine research and product development.
- 4.4. The founding scientists state that through their technology they will progress research and production of medicine and vaccine products in a facility built in the Diaspora University Town – Kenya.
- 4.5. The founding scientists state that their capital input in the company shall be the technologies of which they shall receive shares and their return shall be from profitability of the company of sale of share capital allocated once they make company successful through the products.

4.6. The founding scientists state that the facility will be applied in the production of the following tabulated products and other products they shall innovate:

PRODUCT NAME	THERAPEUTIC AREA
Insulin	Diabetes
Erythropoietin	Anemia/Cancer/Kidney failure
Factor VIII	Hemophilia
Factor X	Hemophilia
Vascular Endothelial Growth Factor (VEGF)	Cancer and Macular degenerative disease
Follicle-Stimulating Hormone (FSH)	Infertility
Luteinizing Hormone (LH)	Infertility
Human Chorionic Gonadotropin (HCG)	Infertility
Streptokinase	Stroke
Tissue Plasminogen Activator (TPA)	Stroke
Interferon- α	Anti-viral & leukemia
Interferon- β	Multiple Sclerosis & Anti-viral infection
Interferon- γ ,	Cancer & Anti-viral infection
nCovid-19	Vaccine
nCovid-19	Small molecule
Hepatitis-B	Small Molecule/Vaccine
Cervical cancer-HPV	Vaccine
Yellow Fever	Vaccine
Ebola	Vaccine
HIV	Small Molecule
TB	Small molecule
Hepatitis	Small molecule
Opioids & Drug addiction	Small molecule
Mental Health Disorders	Small molecule
Foot & Mouth Disease Virus (FMDV)	Vaccine
Domestic Animal Health	Small molecule & Vaccines

4.7. The Scientists state that they are currently working on and are ready to advance the following products in Kenya once research and production facilities are availed.

1. HIV/AIDS – Small molecule.
2. Diabetes, Insulin – Biosimilar biologic
3. TB – Small molecule product
4. Malaria- Small molecule
5. Cholesterol lowering – Small molecule product
6. SARS-CoV-2 (nCovID-19) vaccine
7. Foot & Mouth Disease virus vaccine

5. Healthcare Standard and Research Benefits

- 5.1. The founding scientists in working on the medicine and vaccines are not just doing this for profit but to improve on the healthcare standards in Kenya and Africa, besides building the biotechnology infrastructure and capacity in Kenya and Africa.
- 5.2. Investors joining in will not just be getting a return on investment but will also be contributing toward availing high-quality medicines at affordable prices as part of meeting the highest standard of healthcare in Kenya and Africa.
- 5.3. The founding scientists and investors will grow the research and education capacity through the company and the university founded, besides establishing collaborations with institutions within and worldwide.

- 5.4. The founding scientists and investors, with the Medicine and Vaccine education, research and production infrastructure, will increase the life expectancy in Kenya that is at 65 years compared to over 79 years in countries where modern medicine and vaccine play a big role in positive improvement in quality of life.

INVESTMENT APPROACH, DEVELOPMENT PERIOD, SHARES TRANSFER AND RETURNS

6. Venture Capital Investment Approach

- 6.1. This investment is set as a venture capital investment approach.
- 6.2. The Kshs 2 billion broken down into 10,000 investments of Kshs 200,000 will be invested by persons based on terms set in this investment document.

7. Kshs 2 Billion Investment Application

- 7.1. The investment of Kshs 2 billion shall be applied towards:
 - a Building two facilities: Research and Production facilities.
 - b Equipment purchases for the facilities.
 - c Purchasing Supplies for the facilities
 - d Making operational the research and production plants.
 - e Capital and financial development costs.
- 7.2. The land where the research and production facilities will be built will be provided by Diaspora University Trust within the Diaspora University Town.

8. Company Development Period

- 8.1. The Company development period of this investment shall be the period started by the investment and ended when the Company shares are listed in the Capital Markets.
- 8.2. The investors in making this investment require the Company to be developed and shares listed in the Share market in the fastest reasonable time possible guided by prevailing market fundamentals.
- 8.3. The Company shall not refund an amount put in as Share Capital during the development period.

9. Transfer of Shares during Company Development Period

- 9.1. During the development period, the transfer of shares shall be per terms set by the Company and Diaspora University Trust.
- 9.2. The transfer of shares shall be an internal transfer through terms set and availed every year to the investors.

10. DUT Credit Loan Finance for Investment

- 10.1. Daktari Biotechnology Limited and Diaspora University Trust have arranged with DUT Credit Limited to offer loans to those investing in the 10,000 investments of Kshs 200,000.
- 10.2. The loan shall be for 100% of the investment amount value or as maybe arranged where an investor wants to put in a percentage in cash and take a lower percentage in loan.
- 10.3. A DUT Credit investment account shall be open and a minimum of 5% of total investment amount deposited.
- 10.4. The loan repayments shall be made from the deposits made progressively to cover monthly loan instalments.
- 10.5. The loan shall be guaranteed by Daktari Biotechnology Ltd. and Diaspora University Trust.

10.6. When an investor is unable to meet the loan payment requirements; the guarantee terms shall be applicable.

11. Revenue and Return on Investment

- 11.1. Daktari Biotechnology Limited shall in the shortest period supported by investment capital, put out products that enable the company to achieve revenue.
- 11.2. Diaspora University Trust shall facilitate the company to achieve revenue through GDP growth systems application, research financing and other plans.
- 11.3. The goal of the Company shall be to achieve profitability in the shortest time possible and to pay dividends toward the investors Share capital.
- 11.4. The listing of shares in a Capital market target goal shall be by the end of 5 Years following the investment and application of investment. The company board of directors shall progressively give a report of this target.

INVESTOR

12. Declaration

- 12.1. By writing my name, signing and filing this agreement I declare I have read, understood, and accepted all terms as so written to become an investor in advancing medicine and vaccine production for Kenya and Africa.
- 12.2. I understand that by executing this agreement I am becoming an investor who is putting in capital to be applied toward building, equipping a medicine and vaccine production facilities (Article 7.)
- 12.3. I understand the development period and transfer of my capital investment (Article 9.)
- 12.4. I will take up _____ investments of **Kshs 200,000** a total of Kshs _____
 - a I have deposited a minimum of 5% of total amount at
EQUITY BANK
DUT Credit Ltd
A/C 0790280245673
 - b I understand the loan issue by DUT Credit Ltd (Article 10.)
- 12.5. I understand this investment shall be governed by and is construed in accordance with Kenya Laws.

Name _____

Address _____

Email _____ Telephone _____

Next of Kin _____ Phone _____

Sign _____ Date _____

A copy shall be received and stamped by Daktari Biotechnology. If one fills online a stamped copy will be produced and words online application indicated on signature line.